Click here to get full coverage on How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily

How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing  Stock Traders Daily

How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily

Click here to get full coverage on Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership - Stock Titan

Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership  Stock Titan

Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership - Stock Titan

Click here to get full coverage on JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN

JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline  MSN

JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail

Click here to get full coverage on JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline  Stocktwits

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits

Click here to get full coverage on A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68 - Moomoo

A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68  Moomoo

A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68 - Moomoo

Click here to get full coverage on Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors - simplywall.st

Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors  simplywall.st

Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors - simplywall.st

Click here to get full coverage on Where is Janux Therapeutics (JANX) Headed According to Analysts? - Yahoo Finance

Where is Janux Therapeutics (JANX) Headed According to Analysts?  Yahoo Finance

Where is Janux Therapeutics (JANX) Headed According to Analysts? - Yahoo Finance

Click here to get full coverage on $JANX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

$JANX stock is up 14% today. Here's what we see in our data.  Quiver Quantitative

$JANX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - Business Wire

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development  Business Wire

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - Business Wire

Click here to get full coverage on JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Zacks Investment Research

JANX Enters Global Oncology Collaboration With BMY, Stock Rises  Zacks Investment Research

JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Zacks Investment Research

Click here to get full coverage on Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake - Stock Titan

Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake  Stock Titan

Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake - Stock Titan

Click here to get full coverage on (JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

(JANX) and the Role of Price-Sensitive Allocations  Stock Traders Daily

(JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Click here to get full coverage on Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38  Moomoo

Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Click here to get full coverage on Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat - Stock Titan

Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat  Stock Titan

Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat - Stock Titan

Click here to get full coverage on Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance

Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop  Yahoo Finance

Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance

Click here to get full coverage on Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote - Stock Titan

Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote  Stock Titan

Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote - Stock Titan

Click here to get full coverage on Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Yahoo Finance

Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)  Yahoo Finance

Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Yahoo Finance

Click here to get full coverage on Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses - Yahoo Finance

Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses  Yahoo Finance

Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses - Yahoo Finance

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Insider sales and option exercises reported for JANX (JANX) in Form 144 filing - Stock Titan

Insider sales and option exercises reported for JANX (JANX) in Form 144 filing  Stock Titan

Insider sales and option exercises reported for JANX (JANX) in Form 144 filing - Stock Titan

Click here to get full coverage on Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance

Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test?  Yahoo Finance

Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance

Click here to get full coverage on Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program - Yahoo Finance

Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program  Yahoo Finance

Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move - Benzinga

Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move  Benzinga

Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move - Benzinga

Click here to get full coverage on Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN

Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57  MSN

Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN

Click here to get full coverage on Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (JANX) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st

Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives  simplywall.st

Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st

Click here to get full coverage on (JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily

(JANX) Volatility Zones as Tactical Triggers  Stock Traders Daily

(JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily

Click here to get full coverage on Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha

Bristol Myers inks licensing deal with Janux for cancer therapy  Seeking Alpha

Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha

Click here to get full coverage on Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Decreases By 22.7% - MarketBeat

Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Decreases By 22.7%  MarketBeat

Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Decreases By 22.7% - MarketBeat

Click here to get full coverage on Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance

Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies  Yahoo Finance

Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance

Click here to get full coverage on Responsive Playbooks and the JANX Inflection - Stock Traders Daily

Responsive Playbooks and the JANX Inflection  Stock Traders Daily

Responsive Playbooks and the JANX Inflection - Stock Traders Daily

Click here to get full coverage on 71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed - Stock Titan

71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed  Stock Titan

71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed - Stock Titan

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Yahoo Finance

Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007  Yahoo Finance

Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Yahoo Finance

Click here to get full coverage on Janux (Nasdaq: JANX) Schedules Virtual Event on JANX007 Phase 1a/1b mCRPC Data - Stock Titan

Janux (Nasdaq: JANX) Schedules Virtual Event on JANX007 Phase 1a/1b mCRPC Data  Stock Titan

Janux (Nasdaq: JANX) Schedules Virtual Event on JANX007 Phase 1a/1b mCRPC Data - Stock Titan

Click here to get full coverage on Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed - simplywall.st

Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed  simplywall.st

Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed - simplywall.st

Click here to get full coverage on Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - simplywall.st

Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data  simplywall.st

Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - simplywall.st

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz

Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial  Finviz

Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz

Click here to get full coverage on With Janux Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis

With Janux Therapeutics Stock Sliding, Have You Assessed The Risk?  Trefis

With Janux Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis

Click here to get full coverage on Barclays downgrades Janux Therapeutics (JANX) - MSN

Barclays downgrades Janux Therapeutics (JANX)  MSN

Barclays downgrades Janux Therapeutics (JANX) - MSN

Click here to get full coverage on Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial - Yahoo Finance

Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial  Yahoo Finance

Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial - Yahoo Finance

Click here to get full coverage on Janux (Nasdaq: JANX) reports PSA declines, CRS profile in JANX007 mCRPC trial - Stock Titan

Janux (Nasdaq: JANX) reports PSA declines, CRS profile in JANX007 mCRPC trial  Stock Titan

Janux (Nasdaq: JANX) reports PSA declines, CRS profile in JANX007 mCRPC trial - Stock Titan

Click here to get full coverage on UBS downgrades Janux Therapeutics (JANX) - MSN

UBS downgrades Janux Therapeutics (JANX)  MSN

UBS downgrades Janux Therapeutics (JANX) - MSN

Click here to get full coverage on Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans  simplywall.st

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Click here to get full coverage on Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha

Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data  Seeking Alpha

Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector - DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector  DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector - DirectorsTalk Interviews

Click here to get full coverage on Janux Therapeutics Adjusts Board Class Structure for Director - TipRanks

Janux Therapeutics Adjusts Board Class Structure for Director  TipRanks

Janux Therapeutics Adjusts Board Class Structure for Director - TipRanks

Click here to get full coverage on Janux Therapeutics | ARS: Annual Report to Security Holders - Moomoo

Janux Therapeutics | ARS: Annual Report to Security Holders  Moomoo

Janux Therapeutics | ARS: Annual Report to Security Holders - Moomoo

Click here to get full coverage on Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st

Janux Therapeutics Repeat Insider Selling Not A Positive Indicator  simplywall.st

Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st

Click here to get full coverage on Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors  Business Wire

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire

Click here to get full coverage on JonesTrading Keeps Their Buy Rating on Janux Therapeutics Inc (JANX) - The Globe and Mail

JonesTrading Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)  The Globe and Mail

JonesTrading Keeps Their Buy Rating on Janux Therapeutics Inc (JANX) - The Globe and Mail

Click here to get full coverage on Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb  Stocktwits

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits

Click here to get full coverage on Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 - Business Wire

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014  Business Wire

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 - Business Wire

Click here to get full coverage on Evercore Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - 富途牛牛

Evercore Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23  富途牛牛

Evercore Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - 富途牛牛

Click here to get full coverage on Janux commences participant dosing in Phase I JANX011 trial - Clinical Trials Arena

Janux commences participant dosing in Phase I JANX011 trial  Clinical Trials Arena

Janux commences participant dosing in Phase I JANX011 trial - Clinical Trials Arena

Click here to get full coverage on Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen - MarketBeat

Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen  MarketBeat

Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen - MarketBeat

Click here to get full coverage on Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN

Janux secures $35 million milestone payment from Bristol Myers Squibb  MSN

Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN

Click here to get full coverage on Truist cuts Janux Therapeutics stock price target on competition - Investing.com

Truist cuts Janux Therapeutics stock price target on competition  Investing.com

Truist cuts Janux Therapeutics stock price target on competition - Investing.com

Click here to get full coverage on Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - ChartMill

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment  ChartMill

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - ChartMill

Click here to get full coverage on Morning Market Movers: TAOP, JANX, MDB, ABTC See Big Swings - RTTNews

Morning Market Movers: TAOP, JANX, MDB, ABTC See Big Swings  RTTNews

Morning Market Movers: TAOP, JANX, MDB, ABTC See Big Swings - RTTNews

Click here to get full coverage on Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Business Wire

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment  Business Wire

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Business Wire

Click here to get full coverage on Janux lets the genie out of the bottle | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Janux lets the genie out of the bottle | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

Janux lets the genie out of the bottle | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Click here to get full coverage on JANX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus

JANX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating |  GuruFocus

JANX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus

Click here to get full coverage on Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade) - Seeking Alpha

Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)  Seeking Alpha

JANX

Price Chart

Key Statistics

Technicals

About JANX

Latest News

How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily

Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership - Stock Titan

JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN

Advanced Charts

Top Gainers

Top Losers